Takeda, Others Look To Overseas Growth To Offset Sluggish Japan Market
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical and fellow Japanese drug makers share a need to look abroad for ways to increase business in a shrinking domestic market. That need was behind Takeda's largest-ever acquisition bid by a Japanese drug maker for a foreign firm, the $8.8 billion offer for the U.S. biotech Millennium Pharmaceuticals. Takeda has a weak business structure in the U.S. and Europe when compared with foreign competitors and needed an acquisition. The domestic pharmaceutical market is considered sluggish despite 4.6 percent growth last year. (Click here for more - a subscription may be required
You may also be interested in...
Japan’s Pharmas Need R&D Reform: Tokyo Conference
TOKYO - The pharmaceutical market is rapidly increasing in complexity and pharmaceutical companies need to strengthen their 'mekiki ryoku' - translated 'eye for good judgment' in Japanese - said Ryoichi Inoue of Pharma Marketing Consultant, who is a former marketing executive at Roche in Japan
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.